- Home
- SRG vs MOLN Comparison
SRG vs MOLN Comparison
Compare SRG & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SRG | MOLN |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.0M | 157.8M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SRG | MOLN |
|---|---|---|
| Price | $3.59 | $4.33 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.75 |
| AVG Volume (30 Days) | ★ 194.3K | 5.2K |
| Earning Date | 11-14-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,406,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,000.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.43 | $3.36 |
| 52 Week High | $4.56 | $5.91 |
Technical Indicators
Market Signals| Indicator | SRG | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 47.38 | 53.51 |
| Support Level | $3.38 | $4.13 |
| Resistance Level | $3.78 | $4.57 |
| Average True Range (ATR) | 0.13 | 0.14 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 54.17 | 54.03 |
Price Performance
Historical ComparisonAbout SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, and leasing of diversified and mixed-use properties throughout the United States.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.